ACUTE MYELOID LEUKEMIA

This study looks at whether older or frail patients with acute myeloid leukemia (AML) can safely take a shorter course of the drug venetoclax, based on their bone marrow results on Day 14, instead of the standard longer course. About 250 participants will be randomly assigned to …

This study tests whether adding ivosidenib to oral azacitidine (Onureg) can help prevent acute myeloid leukemia (AML) from returning in patients over 55 who have a specific IDH1 mutation and are already in remission after chemotherapy. About 60 participants will take both pills d…

This study tests a new approach for adults with relapsed or refractory acute myeloid leukemia (AML) who have active disease. It uses a radioactive drug (131I-apamistamab) combined with low-dose radiation and chemotherapy before a stem cell transplant. The goal is to see if this h…

This early-phase trial tests a combination of two drugs, olutasidenib and ziftomenib, in about 20 adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to treatment. The first part finds the safest dose, and the second part checks if that …

This study tests a drug called ziftomenib for adults with a specific genetic type of acute myeloid leukemia (AML) who are not healthy enough for standard chemotherapy. The drug blocks a protein called menin that helps cancer cells grow. The goal is to see if it can control the le…

This early-phase study tests a new drug called PLM-102 in 12 adults whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The main goal is to find the highest safe dose and monitor side effects. Participants will receive PLM-102 and be closely w…

This study tests whether giving tailored maintenance therapy after a stem cell transplant can prevent relapse in people with myeloid cancers like leukemia or myelodysplastic syndrome. About 450 adults will be assigned to treatment based on whether tests detect leftover cancer cel…

This early-stage trial tests a drug called pivekimab sunirine in about 18 children whose acute myeloid leukemia (AML) has come back or not responded to standard treatments. The main goals are to check safety and how the drug moves through the body. Participants receive the drug b…

This study compares two ways of giving donor immune cells (DLI) after a stem cell transplant to prevent cancer from coming back in people with hard-to-treat acute myeloid leukemia or myelodysplastic syndromes. About 200 participants will be randomly assigned to receive DLI either…

This study tests whether adding the drug olutasidenib to standard treatments helps people with certain blood cancers (AML or MDS) that have an IDH1 gene mutation. About 132 adults will receive either standard therapy alone or with olutasidenib. The goal is to see if the combinati…

This trial tests a new way to do stem cell transplants for young adults (ages 16-55) with very aggressive acute myeloid leukemia that hasn't responded to chemo or has high-risk gene changes. Participants get a transplant using umbilical cord blood plus extra infusions of white bl…

This study tests a new drug called BL-M11D1 combined with either standard chemotherapy (cytarabine + daunorubicin) or targeted therapy (venetoclax + azacitidine) for adults newly diagnosed with acute myeloid leukemia. The goal is to see if the combination is safe and works better…

This early-stage study tests a new drug called axatilimab added to standard chemotherapy for people with a specific, high-risk form of acute myeloid leukemia (AML) that has a TP53 mutation or deletion. The goal is to find the safest dose of axatilimab and see how well the combina…

This study tests a specific chemotherapy combination (thiotepa, busulfan, and fludarabine) given before a stem cell transplant from a half-matched donor. It includes 93 older adults (ages 55-75) with acute myeloid leukemia in first remission. The goal is to see if this approach c…

This study tests whether adding two drugs (SHR2554 and azacitidine) to standard chemotherapy before a stem cell transplant can lower the chance of leukemia returning. It includes 160 people aged 15-60 with high-risk or hard-to-treat acute leukemia or myelodysplastic syndrome. Par…

This early-phase study tests whether giving ruxolitinib followed by ruxolitinib plus azacitidine after a stem cell transplant is safe for adults with acute myeloid leukemia (AML). The goal is to prevent graft-versus-host disease (a common transplant complication) and delay or sto…

This study tests whether the antibiotic levofloxacin can safely lower infection risk in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) who are receiving chemotherapy as outpatients. About 75 adults will be randomly assigned to take levofloxacin or rece…

This study looks at a stem cell transplant from a half-matched donor for adults aged 18-65 with acute myeloid leukemia (AML) that has returned or not responded to treatment. After the transplant, patients receive extra medicines and immune cells to help prevent the cancer from co…

This study tests whether the drug interferon-α can help prevent cancer from coming back in people with a specific genetic mutation (TP53) in acute myeloid leukemia or myelodysplastic syndromes. All participants have already had a stem cell transplant and show no signs of cancer. …

This early-phase study tests a new drug called lonitoclax combined with azacitidine in 66 adults with acute myeloid leukemia (AML) that has returned or not improved after prior therapy. The main goal is to find the safest dose and see if the combination can shrink or control the …

This early-stage study tests whether donor immune cells collected after exercise can better prevent or treat leukemia relapse in patients who had a stem cell transplant. About 94 participants with various blood cancers will receive these special cells either to prevent relapse or…

This early-phase study tests whether adding a new drug called eganelisib to two standard AML treatments (venetoclax and azacitidine) is safe and helps control the disease. It enrolls 48 adults with AML that has returned or not responded to prior therapy. The main goal is to find …

This study is for adults aged 60 and older with newly diagnosed acute myeloid leukemia (AML) who cannot handle strong chemotherapy. It compares two treatment schedules: the standard duration of venetoclax plus ASTX727 versus a shorter course of venetoclax plus ASTX727. The goal i…

This study tests whether combining standard chemotherapy with newer drugs can better eliminate leftover leukemia cells in adults aged 18-59 with acute myeloid leukemia (AML) before they receive a stem cell transplant. About 184 participants will be assigned to one of four treatme…

This early-phase trial tests a new type of CAR-T cell therapy for adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The therapy uses donor-derived 'universal' CAR-T cells that target a protein called CLL1 found on most AML cells.…

This study tests a daily pill called revumenib in adults with certain types of acute myeloid leukemia (AML) who have had a stem cell transplant. The goal is to see if taking this pill after transplant helps keep the cancer from coming back. About 144 participants will be randomly…

This study tests whether adding the drug venetoclax to standard chemotherapy before and after a stem cell transplant can help prevent acute myeloid leukemia (AML) from coming back. About 244 adults with AML in first remission will receive either venetoclax or a placebo alongside …

This study tests whether a combination of venetoclax and azacitidine works better than standard chemotherapy as a short-term treatment before a stem cell transplant in adults with high-risk acute myeloid leukemia (AML) who are already in remission. About 216 participants will be …

This study tests whether dental wipes containing xylitol, a natural sugar that limits bacteria growth in the mouth, can reduce bloodstream infections in children and young adults (ages 1-25) with acute myeloid leukemia (AML). Participants will use either xylitol wipes or plain wi…

This study looks at whether medical hypnosis or virtual reality can lower anxiety in adults with acute myeloid leukemia during their first round of chemotherapy. About 99 participants will be split into three groups: standard care alone, standard care plus hypnosis, or standard c…

This study tests a new, standardized way to measure a type of immune cell called iNKT in the blood of 75 patients who have had a stem cell transplant for leukemia. The goal is to see if the levels of these cells can help predict serious complications like graft-versus-host diseas…

This study will follow 400 children and teens who have survived blood cancers like leukemia and lymphoma. Researchers want to understand the long-term health problems these survivors face and create a structured follow-up plan using an electronic platform. The goal is to improve …

This study looks at whether less fit adults with acute myeloid leukemia (AML) are willing to let a computer randomly assign them to lower- or higher-intensity chemotherapy. The goal is to see if this approach is acceptable to patients, which could help design larger trials to fin…

This study will follow 80 newly diagnosed adults with acute myeloid leukemia (AML) to see how their blood clotting changes before and after intensive chemotherapy. The goal is to better understand bleeding risks and improve care. Participants will receive standard treatment and h…

This study tests whether a single injection of motixafortide can help find leftover leukemia cells (called measurable residual disease, or MRD) in the blood of people with acute myeloid leukemia (AML) who have finished their first round of chemotherapy. Ten adults who are in remi…

This study is testing a mobile app called my.naviGATE for teens and young adults (ages 15-24) who have finished cancer treatment. The app provides personalized education, peer support, and tracks how patients are doing. Researchers want to see if using the app helps patients feel…